TrialClinical trialPHN-02832026-10-29 19:00 CT
Combination Gerotherapeutic Interventions for Healthspan Improvement
Source · ClinicalTrials.gov: peptide AND aging
TLDR
ClinicalTrials.gov lists a 90-day randomized, controlled pilot trial of combination gerotherapies as completed. The study was designed to enroll up to 30 participants across three arms to explore longevity-related outcomes; the excerpt provides no results.
01—Key points
- 01The planned study size was 10 participants per arm: control, multi-therapy, and comprehensive therapy.
- 02Both intervention arms included B12, Naltrexone, Metformin, and NAD+; comprehensive therapy also included Rapamycin, GSH, and Infinite Supplement.
- 03The excerpt describes a proof-of-concept study, without reporting outcomes.
Why it matters Editorial
The trial explores combination interventions for longevity-related outcomes, but the excerpt does not establish healthspan benefits.
Summary generated with AI and reviewed by an editor. The original source governs; summaries can contain errors. Information only — not medical advice. Full disclaimer.
No related news yet.